A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily
1996

Daily Oral Administration of Imiquimod in Cancer Patients

Sample size: 21 publication Evidence: low

Author Information

Author(s): P Savage, V Horton, J Moore, M Owens, P Witt, ME Gore

Primary Institution: Royal Marsden Hospital

Hypothesis

Can daily oral imiquimod induce interferon production and have anti-tumor effects in patients with refractory cancer?

Conclusion

Daily administration of imiquimod activates the interferon production system but can lead to significant toxicity at higher doses.

Supporting Evidence

  • Imiquimod was well tolerated at lower doses with no significant toxicity.
  • At higher doses, significant dose-related toxicities were observed.
  • Biological activity was confirmed by significant rises in peripheral blood mononuclear cell 2-5A synthetase levels.

Takeaway

This study tested a new cancer treatment called imiquimod, which is taken by mouth. It showed some promise in helping the body fight cancer, but it also caused some side effects.

Methodology

A phase I clinical trial with 21 patients receiving daily oral doses of imiquimod at varying levels.

Limitations

Only three patients completed the treatment course, and the study had a small sample size.

Participant Demographics

21 patients (9 men, 12 women) aged 30 to 67 years, with advanced refractory cancer.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication